Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients

Cancer Science

Volumn 104, Issue 10, 2013, Pages 1285-1294

  Takahashi, Ryuji ^a   Ishibashi, Yukinao ^a   Hiraoka, Koji ^a   Matsueda, Satoko ^a   Kawano, Kouichirou ^a   Kawahara, Akihiko ^a   Kage, Masayoshi ^a   Ohshima, Koichi ^a   Yamanaka, Ryuya ^a   Shichijo, Shigeki ^a   Shirouzu, Kazuo ^a   Itoh, Kyogo ^a   Sasada, Tetsuro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANCER VACCINE; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; PEPTIDE VACCINE; SERUM AMYLOID A; SORAFENIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALVEOLAR SOFT PART SARCOMA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER IMMUNIZATION; CANCER SURVIVAL; CELLULAR IMMUNITY; CHONDROSARCOMA; CLEAR CELL SARCOMA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DYSPNEA; EPITHELIOID SARCOMA; FEASIBILITY STUDY; FEMALE; FEVER; HLA TYPING; HUMAN; HUMORAL IMMUNITY; HYPOALBUMINEMIA; INJECTION SITE REACTION; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; LUNG METASTASIS; LYMPHOCYTOPENIA; MALAISE; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT NEURILEMOMA; NAUSEA; NEUTROPENIA; OSTEOSARCOMA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; SOFT TISSUE SARCOMA; SURVIVAL TIME; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TUMOR IMMUNITY;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; INDIVIDUALIZED MEDICINE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; SALVAGE THERAPY; SARCOMA; SOFT TISSUE NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VACCINATION; VACCINES, SUBUNIT; YOUNG ADULT;

EID: 84884988761     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12226     Document Type: Article

References (25)

1. Maki RG. Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Curr Opin Oncol 2001; 13: 270-4.
2. Maki RG. Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 2006; 18: 363-8.
3. Chawla SP, Staddon AP, Baker LH et al. Phase II study of mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012; 30: 78-84.
4. Pappo AS, Patel SR, Crowley J et al. R1507, a monocloncal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study. J Clin Oncol 2011; 29: 4541-7.
5. Jungbluth AA, Antonescu CR, Busam KJ et al. Monophaseic and biphasic synoviral sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 2001; 94: 252-6.
6. Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP. Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med 2008; 6: 23.
7. Ayyoub M, Taub RN, Keohan ML et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004; 4: 7.
8. Ayyoub M, Brehm M, Metthez G et al. SSX antigens as tumor vaccine targets in human sarcoma. Cancer Immun 2003; 3: 13.
9. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA et al. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 2007; 120: 67-74.
10. Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K. Overcoming the hurdles of randomized clinical trials of therapeutic cancer vaccines. Eur J Cancer 2010; 46: 1514-9.
11. Terasaki M, Shibui S, Narita Y et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011; 29: 337-44.
12. Yanagimoto H, Shiomi H, Satoi S et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 2010; 24: 795-801.
13. Hattori T, Mine T, Komatsu N et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 2009; 58: 1843-52.
14. Noguchi M, Kakuma T, Uemura H et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 1001-9.
15. Terazaki Y, Yoshiyama K, Matsueda S et al. Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. Cancer Sci 2012; 103: 638-44.
16. Noguchi M, Mine T, Komatsu N et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2011; 10: 1266-79.
17. Komatsu N, Shichijo S, Maeda Y, Itoh K. Measurement of interferon-gamma by high-throughput fluorometric microvolume assay technology system. J Immunol Methods 2002; 263: 169-76.
18. Imanishi T, Akazawa T, Kimura A. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T, eds. HLA 1991, vol. 1. Oxford: Oxford Scientific Publications, 1992; 1065-220.
19. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 109-19.
20. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 3375-83.
21. Marigo I, Bosio E, Solito S et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010; 32: 790-802.
22. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185: 2273-84.
23. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10: 248-56.
24. Minchom A, Jones RL, Fisher C et al. Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma 2010; 2010: 264360.
25. Garbay D, Maki RG, Blay JY et al. Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. Ann Oncol 2013; 24: 1924-30.